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Symptoms of Multiple Sclerosis (MS) are related to a progressive and strong impact
on patient’s quality of life (QoL). PRIMUS questionnaire is a MS-specific-instrument
to assess QoL. OBJECTIVES: To assess QoL in MS patients using the PRIMUS ques-
tionnaire and the relationships between QoL, disease duration and EDSS disability.
MATERIAL AND METHODS: Non-interventional, cross-sectional and multicenter
study. A total of 261 patients, 17 years with relapsing-remitting or secondary-
progressive MS (RRMS/SPMS), treated with interferon beta-1b (6 months). PRIMUS
questionnaire has three subscales: symptoms, activity limitations and QoL. For the
present study, self-assessed changes were evaluated for QoL (0-22 score) and ac-
tivity limitation (0-38 score) subscales. The higher scores the better QoL and the
greater activity limitation. Correlations between PRIMUS-QoL and EUROQoL-5D,
and with visual analog scale (VAS) were evaluated using Spearman-coefficient (S).
RESULTS: Mean (SD) age was 41.7(10.3) years (61.3% women), 83.9% were RRMS
diagnosed. Mean time since diagnosis was 7.65.8 years, higher in SPMS (6.9 5.2
vs. 11.27.4, p0.0001). Mean EDSS disability was 2.61.75 (5.11.3 SPMS vs.
2.11.4 RRMS, p0.0001). PRIMUS-QoL was better in RRMS patients: 18.36.8 vs.
9.97.1 (p0.0001), getting worse as time from diagnosis increased (p0.01) and
with patient’s disability (18.86.6 in early stages [EDSS3.5] and 8.46.3 in ad-
vanced ones [EDSS5], p0.0001). PRIMUS-activity showed a relationship between
loss of activity with disease duration (p0.0001) and patient’s disability (p0.0001).
PRIMUS-QoL showed a strong negative correlation (S-0.7869) with EUROQoL-5D
(as higher EUROQoL scores indicate worse QoL) and positive correlation with the-
VAS (S 0.7272). PRIMUS-activity showed a very strong correlation (S0.8179) with
EUROQoL-5D as well as a strong negative correlation (S-0.7571) with the VAS.
CONCLUSIONS: The QoL of MS patients changes according to the disease types and
disability levels, and it progressively worsens with disease duration. PRIMUS ques-
tionnaire has demonstrated to be a good tool for assessing QoL and activity in MS
patients.
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OBJECTIVES:The PDQ-Carer is a 29 item measure of health related quality of life for
use with carers of people with Parkinson’s disease. The original development of the
instrument identified four sub domains measured by the instrument. This study
examined the possibility that the four domains could reasonably be summed to
also provide a single summary index score.METHODS: The PDQ-Carer was admin-
istered in a postal survey of patients and carers registered with local branches of
the Parkinson’s Disease Society of Great Britain. Data from the four dimensions of
the PDQ-Carer was subjected to higher order factor analyses. This produced a
single factor suggesting that a single index can be calculated from the measure.
Content validity of the measure was assessed by correlating results with the ‘Gen-
eral Health Perceptions’ scale of the SF-36, a generic measure of health status.
RESULTS: A total of 236 carer questionnaires were returned, a response rate of
60.9%. The mean age of the sample was 68.2 years (SD 9.49; range 25-89 years);
63.5% females, 21.3% males. Higher order principle components factor analysis
produced one factor, accounting for 85.5% of the variance. Consequently it was
decided that the scores of the four domains could be summed to produce a single
index figure. The psychometric properties of this index were explored using reli-
ability tests and tests of construct validity. The newly derived single index was
found to be both internally reliable (alpha0.94) and supported by construct valid-
ity (correlation with GHP0.50, p0.001).CONCLUSIONS:The analysis undertaken
here indicates that data from the PDQ-Carer can be presented in summary form.
The index will provide an overall indication of the impact of caring. Furthermore,
the single index reduces the number of statistical comparisons, and hence the role
of chance, when exploring data from the PDQ-Carer.
PND58
EFFECTS OF BG-12 ON QUALITY OF LIFE IN RELAPSING–REMITTING MULTIPLE
SCLEROSIS: FINDINGS FROM THE PHASE 3 CONFIRM STUDY
Kita M1, Fox RJ2, Phillips JT3, Hutchinson M4, Havrdova E5, Sarda SP6, Kong J6, Viglietta
V6, Sheikh SI6, Dawson KT6
1Virginia Mason Medical Center, Seattle, WA, USA, 2Mellen Center for Multiple Sclerosis
Treatment and Research, Cleveland Clinic, Cleveland, OH, USA, 3Multiple Sclerosis Program,
Baylor Institute for Immunology Research, Dallas, TX, USA, 4St Vincent’s University Hospital,
Dublin, Ireland, 5Department of Neurology, First Faculty of Medicine, Charles University in
Prague, Prague, Czech Republic, 6Biogen Idec Inc., Weston, MA, USA
OBJECTIVES: To report the impact of BG-12 (dimethyl fumarate) on patient health-
related quality of life (HRQoL) in CONFIRM, a 2-year, placebo-controlled study of
efficacy and safety of BG-12 in patients with relapsing–remitting multiple sclerosis
(RRMS). METHODS: Patients aged 18–55 years with RRMS (McDonald criteria 2005)
and Expanded Disability Status Scale score 0–5.0 were randomized 1:1:1:1 to oral
BG-12 240 mg twice (BID) or three times daily (TID), placebo, or subcutaneous glati-
ramer acetate (GA) 20 mg/day (reference comparator arm). A Short Form (SF)-36
questionnaire was administered to assess health status and HRQoL on 8 multi-item
100-point scales at baseline, 24 weeks, 1 year and 2 years. These scores were used
to calculate Physical Component Summary (PCS) and Mental Component Sum-
mary (MCS) scores. In addition, patients’ global impression of well-being was as-
sessed at baseline and every 3 months using a 100-point visual analogue scale
(VAS). Higher scores indicated better HRQoL. RESULTS: The intent-to-treat popu-
lation comprised 1,417 patients. Mean PCS scores increased from baseline to 2
years with BG-12 BID (0.49) and TID (0.33) versus a decrease with placebo
(0.71), indicating significantly improved (BID)/a trend toward better (TID) physical
health and well-being relative to placebo (p0.0217 and p0.0519, respectively).
With GA, mean PCS score increased by 0.42 at 2 years (p0.0259 versus placebo).
SF-36 MCS scores showed similar trends but results were not statistically signifi-
cant. Mean changes from baseline to 2 years in VAS scores were 0.3, 0.3 and 2.1
with BG-12 BID, TID and GA, respectively, versus 3.9 with placebo (p0.0003,
p0.0025 and p0.0001, respectively), indicating a significantly improved sense of
well-being with active treatment. CONCLUSIONS: Together with the significant
improvement in clinical and neuroradiological measures, benefits on patient-re-
ported HRQoL further support the potential for BG-12 to become a valuable oral
treatment option for patients with relapsing MS.
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OBJECTIVES:Huntington’s disease (HD) is a neurodegenerative disease that causes
movement disorders, and cognitive and psychological deterioration; leading to
considerable burden for patients and their families. The paucity of research into
the impact of HD on the quality of life (QoL) of family carers led Aubeeluck and
Buchanan to develop and validate a disease-specific QoL measure to evaluate care-
givers’ QoL, and assess the efficacy of therapeutic interventions. This current study
aimed to validate a shortened version of the HD QoL Battery for Carers (HDQoL-C)
in France and Italy. METHODS: The shortened version of the HDQoL-C comprised
two components: the satisfaction with life component (3 items) and the feelings
about living with HD(17 items). It was translated forwards and backwards by native
speakers. 301 family carers completed the questionnaire. While face validity was
studied through item completion, internal validity was evaluated using factorial
structure and internal consistency. Differential item functioning (DIF) analyses
were also performed to test whether all items behaved in the same manner among
the country subgroups. External validation was tested using known-group compar-
ison analyses between three severity subgroups, according to dependence, global
clinical severity and motor severity. RESULTS: The translated short version
showed satisfactory face validity with few missing data (up to 6%) and a good
reliability despite the item reduction (Cronbach’s alpha coefficients of around 0.8
for both components). The factor analysis was comparable to the original version,
with the variable distribution according to the two factors being the same. No
significant DIF between France and Italy was detected. Carers who cared for pa-
tients with less clinically severe symptoms of HD reported significantly better QoL
than carers of patients with more clinically severe symptoms. CONCLUSIONS:
These findings indicate that the HDQoL-C is multi-lingual, multi-cultural and eas-
ily applicable in other languages.
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OBJECTIVES: Peripheral neuropathic pain (PNP) is a complex type of pain initiated
by a primary lesion or dysfunction in the nervous system and causes large impact
on health related quality of life (HRQL). While PNP in diabetes is in focus much less
attention is given to non-diabetic PNP. The main aims of present study were to
screen patients in GP practices for non-diabetic PNP, assess their HRQL and explore
key influential variables. METHODS: Non-diabetic patients aged 30 years were
recruited in 10 general practices in Hungary. At first, patients filled in the PainDe-
tect Questionnaire (PD-Q). Patients achieving 13 PD-Q score (unclear or possible
neuropathic pain) were further assessed by DN4 (Neuropathic Pain Diagnostic
Questionnaire). The cut-off value for the diagnosis of neuropathic pain in the DN4
is a total score of 4/10. Patients with PD-Q score 18 or DN4 score 4 were consid-
ered to be PNP patients. They completed the EQ-5D questionnaire and GPs provided
demographic data. RESULTS: One hundred and eleven patients with non-diabetic
PNP were selected. Among them there were more women (69%), mean age was 62
(SD14) years. Only 15 (14%) patients have already had prior PNP diagnosis at
inclusion. EQ-5D index showed 58% decrease compared to a perfect health state
and 44% decrease to the gender and age matched Hungarian population (0.42 vs.
0.75, p0.001). The pain/discomfort dimension was the most affected in the EQ-5D,
96% of patients reported some or serious problem. Similar ratios for mobility, self-
care, usual activities and anxiety dimensions were 83%, 37%, 82% and 83%. Average
(SD) EQ-5D score of patients with mild, moderate and severe average pain were 0.56
(0.29), 0.43 (0.29) and 0.29 (0.27). The differences were significant (p0.014).
CONCLUSIONS: Our research showed that non-diabetic neuropathic pain is poorly
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